Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Hershey Co — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Hershey Co trades at $164.15 (market cap $32.76B). The key difference: Hershey Co is far larger — about 11.5× Dyne Therapeutics Inc. Common Stock's market cap, and Hershey Co pays a 3.56% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Hershey Co for 135 Days on average.
| DYN | HSY | |
|---|---|---|
Market Cap | $2.86B | $32.76B |
Volume | 3,341,579 | 1,118,576 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $236.28 |
52-Week Low | $14.60 | $157.61 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $2.18B | $37.89B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HSY trades at $164.25, up 0.25% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 38.38% gross margins and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus is mixed with 68.57% hold ratings but a $203.69 price target suggesting 24% upside. Recent news highlights dividend resumption and international leadership changes.
HSY presents a value opportunity with reasonable valuation multiples (P/E 22.27) and dividend yield, but faces headwinds from cocoa cost pressures and technical weakness. The stock's investment case hinges on margin recovery and successful execution of brand investments amid competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
